6533b82dfe1ef96bd129138e
RESEARCH PRODUCT
BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update.
Jordi RimolaAlejandro FornerJordi BruixMarta BurrelJosep FusterBruno SangroRobin Katie KelleyRiad SalemJoana Ferrer-fàbregaM. ReigArndt VogelPeter R. GalleAmit G. SingalVincenzo MazzaferroÁNgeles García-criadoC. Ayusosubject
MaleLiver CancerPrognosis predictionmedicine.medical_specialtyCarcinoma HepatocellularTare weightliver transplantation TACEAFPClinical Trials and Supportive ActivitiesClinical SciencesPsychological interventionSeverity of Illness IndexablationsurvivalArticleTAREsurgeryRare DiseasesClinical ResearchMedicineHepatectomyHumansHCCIntensive care medicineStaging systemNeoplasm StagingCancerHepatologyGastroenterology & Hepatologybusiness.industryLiver DiseaseCarcinomaLiver NeoplasmsALBI scoreHepatocellularsystemic treatmentMiddle Agedmedicine.diseasePrognosisBCLCGood Health and Well BeingHepatocellular carcinomaPublic Health and Health ServicesTreatment strategyFemalebusinessLiver cancerDigestive Diseasesdescription
Treatment for hepatocellular carcinoma (HCC) has experienced major advancements since the last update of the official Barcelona Clinic Liver Cancer (BCLC) prognosis and treatment strategy published in 2018. Advancements in the field have emerged in all areas, but in this manuscript, we present those that have primed a change in the strategy and comment why some encouraging data in select interventions are still considered immature and in need of further research to gain their incorporation into an evidence-based model for clinicians and researchers. Finally, we describe the critical insight and expert knowledge that is needed to take clinical decisions in individual patients so that the recommendation takes into account all the needed parameters to allow a personalised approach.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2022-03-01 |